Logo Logo
Hilfe
Hilfe
Switch Language to English

Vlegels, Naomi ORCID logoORCID: https://orcid.org/0000-0001-7420-9411; Knuth, Nicoló L. ORCID logoORCID: https://orcid.org/0009-0001-8912-9366; Steiner, Konstantin A. ORCID logoORCID: https://orcid.org/0009-0006-8071-2658; Zhang, Linjie ORCID logoORCID: https://orcid.org/0009-0006-3002-243X; Vix, Apolline L. ORCID logoORCID: https://orcid.org/0009-0008-4621-4801; Moumin, Dilara ORCID logoORCID: https://orcid.org/0009-0008-6111-1990; Mirzen, Irem ORCID logoORCID: https://orcid.org/0009-0006-7376-0846; Khalifeh, Nada; Forster, Charlotte ORCID logoORCID: https://orcid.org/0009-0007-7611-5241; Gesierich, Benno ORCID logoORCID: https://orcid.org/0000-0003-2842-7105; Müller, Franziska ORCID logoORCID: https://orcid.org/0000-0003-3340-2164; Lohse, Philipp; Filler, Jule ORCID logoORCID: https://orcid.org/0000-0001-8887-3436; Fang, Rong ORCID logoORCID: https://orcid.org/0000-0002-5663-9407; Klein, Matthias; Dimitriadis, Konstantinos ORCID logoORCID: https://orcid.org/0000-0003-0417-2267; Franzmeier, Nicolai ORCID logoORCID: https://orcid.org/0000-0001-9736-2283; Liebig, Thomas; Endres, Matthias ORCID logoORCID: https://orcid.org/0000-0001-6520-3720; Goertler, Michael; Petzold, Gabor C. ORCID logoORCID: https://orcid.org/0000-0002-0145-8641; Wunderlich, Silke ORCID logoORCID: https://orcid.org/0000-0003-1208-3686; Zerr, Inga ORCID logoORCID: https://orcid.org/0000-0002-6722-2463; Field, Thalia S. ORCID logoORCID: https://orcid.org/0000-0002-1176-0633; Pham, Mirko ORCID logoORCID: https://orcid.org/0000-0003-1295-2685; Swartz, Richard H.; Poli, Sven ORCID logoORCID: https://orcid.org/0000-0002-0286-8781; Berrouschot, Jörg; Zafar, Atif; Schneider, Hauke ORCID logoORCID: https://orcid.org/0000-0002-9641-0922; Shankar, Jai J. ORCID logoORCID: https://orcid.org/0000-0002-3707-9723; Aamodt, Anne Hege; Minnerup, Jens; Mandzia, Jennifer L.; Reimann, Gernot; Psychogios, Marios-Nikos; Mundiyanapurath, Sibu ORCID logoORCID: https://orcid.org/0000-0003-4637-4641; Reich, Arno; Yeo, Leonard L. L. ORCID logoORCID: https://orcid.org/0000-0002-4249-0402; Duering, Marco ORCID logoORCID: https://orcid.org/0000-0003-2302-3136; Reidler, Paul; Goyal, Mayank ORCID logoORCID: https://orcid.org/0000-0001-9060-2109; Tymianski, Michael ORCID logoORCID: https://orcid.org/0000-0002-6311-9565; Hill, Michael D. ORCID logoORCID: https://orcid.org/0000-0002-6269-1543; Dichgans, Martin ORCID logoORCID: https://orcid.org/0000-0002-0654-387X und Tiedt, Steffen ORCID logoORCID: https://orcid.org/0000-0002-8817-8457 (2026): Brain-derived tau for monitoring brain injury in acute ischemic stroke. In: Science Translational Medicine, Bd. 18, Nr. 832

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

A specific and accurate blood test for acute brain injury could help monitor infarct growth in ischemic stroke and serve as a surrogate end point in clinical trials. Using a single-molecule detection assay, we assessed plasma brain-derived tau (BD-tau), a marker selectively quantifying tau protein from the central nervous system, in a prospective cohort of 502 patients with acute ischemic stroke with serial blood sampling from admission to day 7. Higher BD-tau concentrations at admission were associated with more extensive early brain injury on computed tomography and predicted larger final infarct volumes. BD-tau increases from admission to day 2 were related to infarct growth. BD-tau concentrations rose until day 7 and were higher in patients with secondary events, including recurrent stroke. After thrombectomy, the rise of BD-tau was smaller in patients with complete versus incomplete recanalization. BD-tau outperformed other blood markers and imaging metrics in predicting 90-day functional outcome across infarct size strata and time points. In an independent multicenter prospective cohort (N = 519), BD-tau showed higher performance than magnetic resonance imaging–derived final infarct volume in predicting functional outcomes at 3, 12, and 36 months. In the biomarker substudy of a phase 3 trial assessing nerinetide in patients with ischemic stroke (N = 193), BD-tau showed predictive performance comparable to the other cohorts, mediated the relationship between recanalization and functional outcome, and showed a 49% smaller increase in the nerinetide group versus placebo. Overall, plasma BD-tau tracked ischemic brain injury over time, outperformed other biomarkers in predicting functional outcomes, and identified possible treatment responses.

Dokument bearbeiten Dokument bearbeiten